FOLH1 and neoplasm: In a small cohort of 13 patients who received targeted alpha radiation therapy with 225Ac-labeled PSMA ligands, those with high baseline immunohistochemical PSMA expression H-score of ≥200, defined semiquantitatively on a scale of 0−300 as a composite of the percentage of immunopositive tumor cells (0−100%) and the staining intensity (0 = negative; 1+ = weak; 2+ = moderate; 3+ = intense), tended to have longer OS compared to those with H-score < 200 (12.8 vs. 1.8 months, respectively) [50].